Pfizer Finds a Foothold After a Solid Q1 2024 Earnings Report

Key PointsPfizer continues to see COVID-19 revenues plummet as Paxlovid revenues dropped 50% and Comirnaty revenues dropped 88% YoY.Despite a 19.5% drop in YoY Q1 2024 revenues, its non-COVID drugs added $12.5 billion to quarterly revenues, and oncology product revenues rose 11$2.15 to $2.35, up from its previous forecast of$2.05 to $2.24 versus$2.21 consensus estimates.5 stocks we like better than PfizerBiopharma giant Pfizer Inc. NYSE: PFE has given back all ...